Screener
Edgewise Therapeutics, Inc. EWTX Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:09 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056713
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Other income | ||
| Interest income | 5,102 | 5,161 |
| Total other income | 5,102 | 5,161 |
| Net loss | (49,013) | (40,798) |
| Other comprehensive income (loss): | ||
| Unrealized loss on available-for-sale securities, net | (929) | (19) |
| Total comprehensive loss | $(49,942) | $(40,817) |
| Net loss per share, basic and diluted | $(0.46) | $(0.43) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Edgewise Therapeutics, Inc.'s net income?
- Edgewise Therapeutics, Inc. (EWTX) reported net income of -$49.01M in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s net income changed year-over-year?
- Edgewise Therapeutics, Inc.'s net income decreased by 20.1% year-over-year, from -$40.8M to -$49.01M.
- What is the long-term trend for Edgewise Therapeutics, Inc.'s net income?
- Over 4 years (2021 to 2025), Edgewise Therapeutics, Inc.'s net income has grown at a 40.7% compound annual growth rate (CAGR), from -$42.81M to -$167.8M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Edgewise Therapeutics, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude